What exactly is Anupam Rasayan buying?

The company is acquiring up to 74.20% of the equity share capital of Bliss GVS Pharma Limited, which gives it control over the listed pharmaceutical firm.

How much is Anupam Rasayan paying for this stake?

The company has not disclosed the financial consideration for the deal in its regulatory filing.

Why is this acquisition significant for Anupam Rasayan?

It marks the company's entry into the pharmaceutical space, representing a shift away from its core business of custom synthesis and specialty chemicals.

The deal is subject to customary approvals. Once finalized, the acquisition will likely trigger the consolidation of Bliss GVS Pharma's financials into Anupam Rasayan's accounts.

M&A · Specialty Chemicals

Anupam Rasayan buys 74% of Bliss GVS Pharma to enter drug sector

The specialty chemicals firm is pivoting into pharmaceuticals by acquiring a controlling stake in the listed drugmaker. Financial terms remain undisclosed.

— 2 earlier stories on Anupam Rasayan India Ltd. →

ANURAS BSE 543275 23 May 2026 · 7:33 PM IST Verify on BSE · NSE

Mkt cap₹15,552 cr

P/E90.40×

ROE3.28%

Debt / eq.0.46

Div yld0.06%

74.20% Controlling equity stake Anupam Rasayan is acquiring in Bliss GVS Pharma.

What's new

Anupam Rasayan is moving into the pharmaceutical sector with a 74.20% stake in Bliss GVS Pharma.
The deal grants Anupam Rasayan control over the listed pharmaceutical entity.
No financial consideration for the acquisition has been disclosed yet.

Why this matters

This is a major pivot for a specialty chemicals firm. By taking control of a separate listed entity, Anupam Rasayan is moving beyond its core custom synthesis business into the drug market. The lack of price disclosure leaves the most important question unanswered.

What we're watching

The total cash outlay required for the acquisition.
How Anupam Rasayan plans to integrate a pharmaceutical firm into its chemicals business.
Regulatory and shareholder approvals required to close the deal.

The full read

Anupam Rasayan is moving into the pharmaceutical sector. The board approved the acquisition of up to 74.20% of Bliss GVS Pharma, a listed drugmaker, in a move that gives the specialty chemicals firm control over a new business line. This is a departure from its core custom synthesis and specialty chemicals operations. While the board approved the deal alongside its annual results, the filing is silent on the price tag. The acquisition is subject to customary approvals. This is a material shift for a mid-cap firm, as it gains a controlling stake in a separate listed entity. The next test is the valuation and the integration strategy. Investors are currently waiting for the financial terms to determine the impact on the balance sheet.

Questions answered

What exactly is Anupam Rasayan buying?: The company is acquiring up to 74.20% of the equity share capital of Bliss GVS Pharma Limited, which gives it control over the listed pharmaceutical firm.
How much is Anupam Rasayan paying for this stake?: The company has not disclosed the financial consideration for the deal in its regulatory filing.
Why is this acquisition significant for Anupam Rasayan?: It marks the company's entry into the pharmaceutical space, representing a shift away from its core business of custom synthesis and specialty chemicals.
What happens next?: The deal is subject to customary approvals. Once finalized, the acquisition will likely trigger the consolidation of Bliss GVS Pharma's financials into Anupam Rasayan's accounts.

Mentioned: Anupam Rasayan · Bliss GVS Pharma

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on ANURAS →

Today · 7:33 PM IST Anupam Rasayan buys 74% of Bliss GVS Pharma to enter drug sector
today Anupam Rasayan revenue jumps 65% in FY26 as margins slip
today Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore